PuSH - Publication Server of Helmholtz Zentrum München: Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Jaeckel, E.* ; Friedman, S.L.* ; Hudecek, M.* ; Protzer, U.

Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases.

J. Hepatol. 83, 1156-1171 (2025)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Hybrid

Abstract
Metrics
Extra information

Endogenous T cells recognize antigens through human leukocyte antigen (HLA)/peptide complexes. However, the polymorphism of HLA has posed significant challenges to the development of broadly applicable adoptive T-cell therapies. Engineered T cells can circumvent this barrier by targeting surface antigens independently from HLA through a synthetic chimeric antigen receptor (CAR) with an antibody-derived recognition domain fused to intracellular signaling motifs. CAR-T cell therapies have transformed the treatment of B-cell malignancies in hematology, and recent studies demonstrate therapeutic potential against solid tumors. This review presents an overview of CAR technology's fundamental principles and achievements, focusing on CAR-T cell applications in hepatic viral infections, autoimmune liver disease, and hepatobiliary tumors. Emerging senolytic therapies that target senescent cells and hepatic fibrosis are highlighted alongside regulatory CAR-T cells that induce liver-specific immune tolerance in transplantation. Future and ongoing research is reviewed that seeks to enhance the specificity, efficacy, and safety of CAR-based therapies as "living drugs" that facilitate targeted, sustained, and personalized interventions for liver diseases.

Impact Factor

Scopus SNIP

Altmetric

33.000

0.000